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Background: Chronic fatigue has a major impact on quality of 
life in MS patients. Its pathogenesis is still poorly understood. 
MS-related tissue damage of different brain structures has been 
related to fatigue. Alternatively, the inflammatory milieu within 
the CNS compartment itself may contribute to fatigue. Therefore, 
we related both volumes from structural brain magnetic resonance 
imaging (MRI) and measures of cerebrospinal fluid (CSF) to 
fatigue in patients with MS. 
Methods: We determined CSF cell count, intrathecal IgG-, IgM- 
and IgA-synthesis and oligoclonal bands in 84 MS patients at time 
of diagnosis. In a subset of 31 patients, CSF was additionally ana-
lysed by flow cytometry. We performed brain MRI after a mean 
follow-up period of 3 years and determined volumes of grey mat-
ter, white matter, white matter lesions, thalamus, putamen, cau-
date nucleus, hippocampus, amygdala and nucleus accumbens. 
Fatigue was quantified by the Fatigue Scale for Motor and 
Cognitive Functions (FSMC) at the time point of MRI. We per-
formed correlation analyses and a multiple regression analysis 
with fatigue as dependent variable and CSF and MRI parameters 
as independent variables controlling for age and total intracranial 
volume (TIV).
Results: No significant correlation was found between fatigue 
and any of the MRI parameters. In contrast, the CSF CD4/CD8-
ratio and the percentage of CD8+ T cells at the time of MS diag-
nosis was associated with the development of fatigue (r=-0.57, 
p=0.001; r=0.55, p=0.001). Correlation of the CSF CD4/CD8-
ratio with fatigue persisted even after correction for the EDSS as 
a global marker for disease severity (r=-0.57, p=0.005). In a mul-
tiple regression analysis with fatigue as dependent variable and all 
CSF and MRI parameters, age and TIV as independent variables, 
the overall model was significant (p=0.035; adjusted R²=0.46) 
and confirmed the significant correlation of the CD4/CD8-ratio 
with fatigue (p=0.005). 
Conclusion: Our data lend support to the idea that the inflamma-
tory milieu in the CNS itself may contribute to the development of 
fatigue in MS.
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